Balanced Risk/Reward Keeps Regeneron at Hold Amid Solid Fundamentals and Pipeline Uncertainty

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on REGN stock, giving a Hold rating on January 27.

Terence Flynn has given his Hold rating due to a combination of factors that balance Regeneron’s solid fundamentals with lingering uncertainties. Regeneron delivered a stronger-than-expected fourth quarter, beating consensus on both earnings and revenue, and management’s 2026 guidance for R&D, SG&A, margins, tax rate, and capital spending supports a healthy financial profile. However, Flynn views these positive results as largely in line with the current market expectations, limiting near-term upside. In addition, adjustments to the financial model following the quarter suggest incremental, not transformational, changes to the outlook.

Terence Flynn’s rating is also shaped by a mixed picture around the Eylea franchise and the company’s pipeline catalysts. While U.S. Eylea sales remained robust and Eylea HD is expected to show sequential demand growth, the legacy dose is anticipated to decline sharply, and prior reductions in patient assistance funding continue to weigh on the branded market. Although Regeneron has renewed its foundation support, the lower overall contribution versus 2024 may sustain some pressure on market dynamics. Finally, Flynn identifies upcoming Phase 3 LAG3 melanoma data as the next major driver for the stock; until those results clarify the longer-term growth trajectory, he sees the risk/reward as balanced, justifying a Hold stance.

Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Bristol-Myers Squibb, and Eli Lilly & Co. According to TipRanks, Flynn has an average return of 10.4% and a 59.64% success rate on recommended stocks.

In another report released on January 27, RBC Capital also maintained a Hold rating on the stock with a $745.00 price target.